AKT1 and cancer: Afatinib irreversibly binds to epidermal growth factor receptor (EGFR) and Her2 and inhibits tyrosine kinase followed by the activation of the Ras‐MAPK and PI3K‐Akt signaling pathway, which play critical roles in the cancer cell proliferation, migration, and survival.